专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0158949A2 HETEROLOGOUS POLYPEPTIDE OF THE TNF FAMILY 审中-公开
标题翻译： TNF家族的异位多糖
公开(公告)号：WO0158949A2
公开(公告)日：2001-08-16
申请号：PCT/US0104121
申请日：2001-02-08
申请人： BIOGEN INC , RENNERT PAUL D , THOMPSON JEFFREY S , AMBROSE CHRISTINE , CACHERO TERESA G
发明人： RENNERT PAUL D , THOMPSON JEFFREY S , AMBROSE CHRISTINE , CACHERO TERESA G
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61K45/00 , A61P1/16 , A61P11/00 , A61P15/00 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/04 , A61P29/00 , A61P35/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P43/00 , C07K14/52 , C07K14/525 , C07K14/705 , C07K19/00 , C12N5/02
CPC分类号： C07K14/52 , A61K38/00 , C07K14/70575
摘要： A newly identified heteromeric ligand of the Tumor Necrosis Factor (TNF)-family, referred to hereinafter as "APBF" has been identifed.
摘要翻译：已经鉴定了新鉴定的肿瘤坏死因子（TNF）家族的异聚配体（以下称为“APBF”）。

2. 发明申请

WO2006094134A2 KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS 审中-公开
标题翻译：用于治疗TH2介导的病症的KIM-1抗体
公开(公告)号：WO2006094134A2
公开(公告)日：2006-09-08
申请号：PCT/US2006/007441
申请日：2006-03-02
申请人： BIOGEN IDEC MA INC. , RENNERT, Paul, D. , MCCOON, Patricia , BAILLY, Veronique , LUGOVSKOY, Alexey
发明人： RENNERT, Paul, D. , MCCOON, Patricia , BAILLY, Veronique , LUGOVSKOY, Alexey
IPC分类号： A61K39/395 , A61P11/06 , A61P37/00 , A61P37/08 , C07K16/28
CPC分类号： A61K39/39533 , A61K2039/505 , C07K16/2803 , C07K2317/34 , C07K2317/73 , C07K2317/74
摘要： Compositions and methods for treating Th2- and ThI -mediated disease are provided.
摘要翻译：提供了治疗Th2-和ThI介导的疾病的组合物和方法。

3. 发明申请

WO9817313A3 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases 审中-公开
标题翻译：可溶性淋巴毒素-β受体，抗淋巴毒素受体抗体和抗淋巴毒素配体抗体作为治疗免疫疾病的治疗剂
公开(公告)号：WO9817313A3
公开(公告)日：1998-07-30
申请号：PCT/US9719436
申请日：1997-10-24
申请人： BIOGEN INC , BROWNING JEFFREY , HOCHMAN PAULA SUSAN , RENNERT PAUL D , MACKAY FABIENNE
发明人： BROWNING JEFFREY , HOCHMAN PAULA SUSAN , RENNERT PAUL D , MACKAY FABIENNE
IPC分类号： A61K45/00 , A61K31/7008 , A61K38/00 , A61K39/395 , A61P31/18 , A61P37/02 , C07K14/715 , C07K16/24 , C07K16/28 , A61K38/17 , A61K38/55
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7151 , C07K16/241 , C07K16/2878 , C07K2319/00 , C07K2319/30
摘要： Compositions and methods comprising "lymphotoxin- beta receptor blocking agents" which block lymphotoxin-ss receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

4. 发明申请

WO1997028267A1 ANTIBODIES AND IMMUNOGLOBULIN FUSION PROTEINS HAVING MODIFIED EFFECTOR FUNCTIONS AND USES THEREFOR 审中-公开
标题翻译：具有改良效应功能的抗体和免疫球蛋白融合蛋白及其用途
公开(公告)号：WO1997028267A1
公开(公告)日：1997-08-07
申请号：PCT/US1997001698
申请日：1997-02-03
申请人： REPLIGEN CORPORATION , GRAY, Gary, S. , CARSON, Jerry , JAVAHERIAN, Kashi , JELLIS, Cindy, L. , RENNERT, Paul, D. , SILVER, Sandra
发明人： REPLIGEN CORPORATION
IPC分类号： C12N15/62
CPC分类号： C07K14/70503 , A61K38/00 , A61K2039/5154 , C07K2319/00
摘要： CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g., CD28 and/or CTLA4) on the surface of T cellsto thereby suppress an immune response in the subject, for example to inhibit transplantation rejection, graft versus host disease or autoimmune responses.
摘要翻译：描述了具有修饰的免疫球蛋白恒定区介导的效应子功能的CTLA4-免疫球蛋白融合蛋白，以及编码融合蛋白的核酸。 CTLA4免疫球蛋白融合蛋白包含两个组分：具有CTLA4活性的第一肽和包含免疫球蛋白恒定区的第二个肽，其被修饰以相对于CTLA4-IgG1融合蛋白减少至少一个恒定区介导的生物效应子功能。本发明的核酸可以整合到各种表达载体中，这又可以指导各种宿主，特别是真核细胞中相应的蛋白质的合成。本文所述的CTLA4-免疫球蛋白融合蛋白可以施用于受试者以抑制抗原呈递细胞上的CTLA4配体（例如B7-1和/或B7-2）与CTLA4配体的受体（例如， CD28和/或CTLA4），从而抑制受试者的免疫应答，例如抑制移植排斥反应，移植物抗宿主病或自身免疫应答。

5. 发明申请

WO2004027026A3 IMPROVED METHODS FOR PREPARING HIGHLY ACTIVE APRIL LIGAND POLYPEPTIDES 审中-公开
标题翻译：制备高活性四核配体多聚体的改进方法
公开(公告)号：WO2004027026A3
公开(公告)日：2005-01-06
申请号：PCT/US0329178
申请日：2003-09-19
申请人： BIOGEN IDEC INC , RENNERT PAUL D , FARRINGTON GRAHAM K , ELDREDGE JOHN K , PELLETIER MARC , HSU YEN-MING
发明人： RENNERT PAUL D , FARRINGTON GRAHAM K , ELDREDGE JOHN K , PELLETIER MARC , HSU YEN-MING
IPC分类号： A61K38/00 , C07K14/705 , A61K38/16 , C07K1/16 , C07K1/18 , C07K1/22 , C07K2/00 , C12N5/00 , C12N7/00 , C12N15/09 , C12N15/63 , C12P21/00
CPC分类号： C07K14/70575 , A61K38/00
摘要： The present invention relates to improved methods for producing biologically active truncated APRIL ligand polypeptides and analogs thereof. The invention further relates to truncated APRIL ligand polypeptides and analogs thereof that retain a high biological activity and may be isolated in high yields, as well as the nucleotide sequences that encode the truncated APRIL ligand polypeptides and analogs thereof. The invention also relates to compositions of the biologically active truncated APRIL ligand polypeptides and analogs thereof. The invention further relates to the use of the biologically active truncated APRIL ligand polypeptides and analogs thereof in promoting cell proliferation.
摘要翻译：本发明涉及用于生产生物活性截短的APRIL配体多肽及其类似物的改进方法。本发明进一步涉及截短的APRIL配体多肽及其类似物，其保留高生物活性并且可以以高产量分离，以及编码截短的APRIL配体多肽及其类似物的核苷酸序列。本发明还涉及生物活性截短的APRIL配体多肽及其类似物的组合物。本发明还涉及生物活性截短的APRIL配体多肽及其类似物在促进细胞增殖中的用途。

6. 发明申请

WO2004027026A2 IMPROVED METHODS FOR PREPARING HIGHLY ACTIVE APRIL LIGAND POLYPEPTIDES 审中-公开
标题翻译：制备高活性四核配体多聚体的改进方法
公开(公告)号：WO2004027026A2
公开(公告)日：2004-04-01
申请号：PCT/US2003/029178
申请日：2003-09-19
申请人： BIOGEN, INC. , RENNERT, Paul, D. , FARRINGTON, Graham, K. , ELDREDGE, John, K. , PELLETIER, Marc , HSU, Yen-Ming
发明人： RENNERT, Paul, D. , FARRINGTON, Graham, K. , ELDREDGE, John, K. , PELLETIER, Marc , HSU, Yen-Ming
IPC分类号： C12N
CPC分类号： C07K14/70575 , A61K38/00
摘要： The present invention relates to improved methods for producing biologically active truncated APRIL ligand polypeptides and analogs thereof. The invention further relates to truncated APRIL ligand polypeptides and analogs thereof that retain a high biological activity and may be isolated in high yields, as well as the nucleotide sequences that encode the truncated APRIL ligand polypeptides and analogs thereof. The invention also relates to compositions of the biologically active truncated APRIL ligand polypeptides and analogs thereof. The invention further relates to the use of the biologically active truncated APRIL ligand polypeptides and analogs thereof in promoting cell proliferation.
摘要翻译：本发明涉及用于生产生物活性截短的APRIL配体多肽及其类似物的改进方法。本发明进一步涉及截短的APRIL配体多肽及其类似物，其保留高生物活性并且可以以高产量分离，以及编码截短的APRIL配体多肽及其类似物的核苷酸序列。本发明还涉及生物活性截短的APRIL配体多肽及其类似物的组合物。本发明还涉及生物活性截短的APRIL配体多肽及其类似物在促进细胞增殖中的用途。

7. 发明申请

WO2006094134A3 KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS 审中-公开
标题翻译： KIM-1抗体治疗TH2介导的病症
公开(公告)号：WO2006094134A3
公开(公告)日：2006-10-19
申请号：PCT/US2006007441
申请日：2006-03-02
申请人： BIOGEN IDEC INC , RENNERT PAUL D , MCCOON PATRICIA , BAILLY VERONIQUE , LUGOVSKOY ALEXEY
发明人： RENNERT PAUL D , MCCOON PATRICIA , BAILLY VERONIQUE , LUGOVSKOY ALEXEY
IPC分类号： A61K39/395 , A61P11/06 , A61P37/00 , A61P37/08 , C07K16/28
CPC分类号： A61K39/39533 , A61K2039/505 , C07K16/2803 , C07K2317/34 , C07K2317/73 , C07K2317/74
摘要： Compositions and methods for treating Th2- and ThI -mediated disease are provided.
摘要翻译：提供了用于治疗Th2-和Th1-介导的疾病的组合物和方法。

8. 发明申请

WO1998017313A2 SOLUBLE LYMPHOTOXIN-BETA RECEPTORS, ANTI-LYMPHOTOXIN RECEPTOR ANTIBODIES, AND ANTI-LYMPHOTOXIN LIGAND ANTIBODIES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES 审中-公开
标题翻译：作为治疗免疫系统疾病的治疗药物的可溶性LYMPHOTOXIN-BETA受体，抗-LYMPHOTOXIN受体抗体和抗-LYMPHOTOXIN LIGAND抗体
公开(公告)号：WO1998017313A2
公开(公告)日：1998-04-30
申请号：PCT/US1997019436
申请日：1997-10-24
申请人： BIOGEN, INC. , BROWNING, Jeffrey , HOCHMAN, Paula, Susan , RENNERT, Paul, D. , MacKAY, Fabienne
发明人： BIOGEN, INC.
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7151 , C07K16/241 , C07K16/2878 , C07K2319/00 , C07K2319/30 , Y02A50/401 , Y02A50/414
摘要： Compositions and methods comprising "lymphotoxin- beta receptor blocking agents" which block lymphotoxin-ss receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
摘要翻译：包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导并且可用于改变免疫疾病，特别是抗体介导的免疫应答。

9. 发明申请

WO2004060041A3 KIM-1 ANTAGONISTS AND USE TO MODULATE IMMUNE SYSTEM 审中-公开
标题翻译： KIM-1拮抗剂和用于调节免疫系统
公开(公告)号：WO2004060041A3
公开(公告)日：2005-01-27
申请号：PCT/US0341294
申请日：2003-12-29
申请人： BIOGEN IDEC INC , RENNERT PAUL D
发明人： RENNERT PAUL D
IPC分类号： A61K38/00 , A61K39/00 , A61K39/395 , A61K47/48 , A61K49/00 , C07K14/705 , C07K16/28 , C07K17/00
CPC分类号： A61K49/0008 , A61K47/60 , A61K2039/505 , C07K14/70503 , C07K16/2803 , C07K2317/76 , C07K2319/30 , C07K2319/32
摘要： The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-gamma by lymphocytes or other immune cells in a mammal. Inhibition of IFN-gamma is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease.
摘要翻译：公开了使用KIM-1拮抗剂抑制T细胞和第二细胞例如抗原呈递细胞之间的信号传导。这种抑制对于治疗包括各种自身免疫性疾病和移植物抗宿主病的疾病是有用的。还公开了使用KIM-1拮抗剂来抑制哺乳动物中淋巴细胞或其他免疫细胞分泌IFN-γ。 IFN-γ的抑制可用于治疗炎性疾病或病症，例如炎症性肠病。

10. 发明申请

WO2004060041A2 KIM-1 ANTAGONISTS AND USE TO MODULATE IMMUNE SYSTEM 审中-公开
标题翻译： KIM-1拮抗剂和用于调节免疫系统
公开(公告)号：WO2004060041A2
公开(公告)日：2004-07-22
申请号：PCT/US2003/041294
申请日：2003-12-29
申请人： BIOGEN IDEC MA INC. , RENNERT, Paul ,D.
发明人： RENNERT, Paul ,D.
IPC分类号： A61K38/00 , A61K39/00 , A61K39/395 , A61K47/48 , A61K49/00 , C07K14/705 , C07K16/28 , C07K17/00
CPC分类号： A61K49/0008 , A61K47/60 , A61K2039/505 , C07K14/70503 , C07K16/2803 , C07K2317/76 , C07K2319/30 , C07K2319/32
摘要： The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-γ by lymphocytes or other immune cells in a mammal. Inhibition of IFN-γ is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease.
摘要翻译：公开了使用KIM-1拮抗剂抑制T细胞和第二细胞例如抗原呈递细胞之间的信号传导。这种抑制对于治疗包括各种自身免疫疾病和移植物抗宿主病的疾病是有用的。还公开了使用KIM-1拮抗剂来抑制哺乳动物中淋巴细胞或其他免疫细胞分泌IFN-γ。 IFN-γ的抑制可用于治疗炎性疾病或病症，例如炎症性肠病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式